Kymera Therapeutics (KYMR) Interest Expenses (2019 - 2026)
Kymera Therapeutics (KYMR) posted quarterly Interest Expenses of $410.6 million for Q1 2026, up 236.61% year-over-year from $122.0 million in Q1 2025, and up 64.2% quarter-over-quarter from $250.1 million in Q3 2025.
Kymera Therapeutics (KYMR) Interest Expenses (2019 - 2026) Analysis & Trends
Kymera Therapeutics (KYMR) has reported Interest Expenses for 8 consecutive years, with $410.6 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Interest Expenses rose 236.61% year-over-year to $410.6 million; the TTM figure through Mar 2026 stood at $410.6 million (up 236.61% YoY), while the FY2025 annual figure was $400.5 million, up 69.55% from the prior year.
- Interest Expenses advanced to $410.6 million in Q1 2026 per KYMR's latest filing, from $250.1 million in the prior quarter.
- Across five years, Interest Expenses topped out at $410.6 million in Q1 2026 and bottomed at $16000.0 in Q4 2024.
- Historically, Interest Expenses has averaged $115.5 million across 5 years, with a median of $122.8 million in 2023.
- Annual changes were most pronounced in 2023 — Interest Expenses surged 79935.48% — and 2024, when it slumped 99.97%.
- Kymera Therapeutics' Interest Expenses stood at $62000.0 in 2022, then soared by 79935.48% to $49.6 million in 2023, then plunged by 99.97% to $16000.0 in 2024, then jumped by 1562743.75% to $250.1 million in 2025, then surged by 64.2% to $410.6 million in 2026.
- Business Quant data shows KYMR's Interest Expenses at $410.6 million in Q1 2026, $250.1 million in Q3 2025, and $134.2 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 439.40 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 52.50 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.70 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 39.74 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 335,572.77 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 218.10 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 82.05 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 20.27 Mn |
| 10 | Kymera Therapeutics | 9.72 Bn | 9.03 Bn | - | 653.81 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 653.81 Mn |
| Jun 30, 2026 | 653.81 Mn |
| Mar 31, 2026 | 410.60 Mn |
| Mar 31, 2026 | 410.60 Mn |
| Sep 30, 2025 | 250.06 Mn |
| Sep 30, 2025 | 250.06 Mn |
| Jun 30, 2025 | 134.25 Mn |
| Jun 30, 2025 | 134.25 Mn |
| Mar 31, 2025 | 121.98 Mn |
| Mar 31, 2025 | 121.98 Mn |
| Dec 31, 2024 | 16,000.00 |
| Dec 31, 2024 | 16,000.00 |
| Sep 30, 2024 | 149.18 Mn |
| Sep 30, 2024 | 149.18 Mn |
| Jun 30, 2024 | 57.03 Mn |
| Jun 30, 2024 | 57.03 Mn |
| Mar 31, 2024 | 131.21 Mn |
| Mar 31, 2024 | 131.21 Mn |
| Dec 31, 2023 | 49.62 Mn |
| Dec 31, 2023 | 49.62 Mn |